Antitumor effect of oxycellulose as a hemostatic during operation.
Oxycellulose, a hemostatic agent used in operation showed antitumor effect in vitro on a murine hepatic cell carcinoma (MH 134), a murine fibrosarcoma (Meth A) and a murine colon carcinoma (Colon 26). The effect was also confirmed in vivo by the survival of mice inoculated with Meth A or MH 134. Eighty milligrams per mouse of this agent, however, showed a toxicity rather than an antitumor effect. The antitumor effect of oxycellulose on Meth A did not compare with that of etoposide or mitomycin C in vivo. The antitumor effect on MH 134 was equal to that of etoposide but not mitomycin C. Oxycellulose inhibited tritium thymidine uptake into Colon 26 cells to the same extent as 5-fluorouracil and mitomycin C and it caused 51Cr-labelled Colon 26 cells but not from 5-fluorouracil or mitomycin C. Oxycellulose decreased a larger number of viable tumor cells than 5-fluorouracil or mitomycin C when the tumor cells were incubated for 24 hours at 37 degrees C. DNA histogram with MH 134 cells showed oxycellulose decreased a ratio of tumor cells in S-phase. These results suggest that the antitumor effect of oxycellulose is cytocidal and phase-specific.
Tokunaga
Y
Y
First Department of Surgery, Aichi Medical University, Japan.
Kojima
T
T
Naruse
T
T
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002455:Cell Division / Q000187:drug effects; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004273:DNA, Neoplasm / Q000096:biosynthesis; D004912:Erythrocytes / Q000187:drug effects / Q000502:physiology; D005047:Etoposide / Q000627:therapeutic use; D005260:Female; D005354:Fibrosarcoma / Q000188:drug therapy* / Q000473:pathology; D006490:Hemostatics / Q000008:administration & dosage / Q000627:therapeutic use*; D065347:Hypromellose Derivatives; D007274:Injections, Intraperitoneal; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy* / Q000473:pathology; D008747:Methylcellulose / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D016685:Mitomycin / Q000627:therapeutic use; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D006490:Hemostatics; D065347:Hypromellose Derivatives; D016685:Mitomycin; D005047:Etoposide; D008747:Methylcellulose